Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certification & Accreditation
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Off-label dermatologic uses of IL-17 inhibitors
By
- AMS
posted
Mar 09, 2020 12:11 PM
0
Recommend
.
0 comments
0 views
Related Content
Off-label studies on ruxolitinib in dermatology: a review
- AMS
Added Jun 09, 2020
Blog Entry
Off-Label studies on anakinra in dermatology: a review
- AMS
Added Apr 22, 2020
Blog Entry
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study
- AMS
Added Aug 13, 2021
Blog Entry
On which evidence can we rely when prescribing off-label methotrexate in dermatological practice? – a systematic review with GRADE approach
- AMS
Added Aug 24, 2021
Blog Entry
Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review
- AMS
Added Sep 25, 2020
Blog Entry
Permalink
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic